Relay Therapeutics (RLAY) Interest Expenses (2019 - 2026)

Relay Therapeutics (RLAY) has reported Interest Expenses for 8 consecutive years, with $365000.0 the latest figure, recorded in Q1 2026.

• In Q1 2026, Interest Expenses fell 59.93% year-over-year to $365000.0; the TTM figure through Mar 2026 stood at $365000.0 (down 59.93% YoY), while the FY2025 annual figure was $480.5 million, up 11.25% from the prior year.
• Interest Expenses rose to $365000.0 in Q1 2026 per RLAY's latest filing, from $6000.0 in the prior quarter.
• Across five years, Interest Expenses topped out at $431.9 million in Q4 2024 and bottomed at $6000.0 in Q4 2025.
• Historically, Interest Expenses has averaged $29.7 million across 5 years, with a median of $3.4 million in 2023.
• Annual changes were most pronounced in 2022 — Interest Expenses surged 22945.0% — and 2025, when it tumbled 100.0%.
• Relay Therapeutics' Interest Expenses stood at $7.6 million in 2022, then surged by 149.47% to $18.9 million in 2023, then surged by 2184.49% to $431.9 million in 2024, then sank by 100.0% to $6000.0 in 2025, then surged by 5983.33% to $365000.0 in 2026.
• Business Quant data shows RLAY's Interest Expenses at $365000.0 in Q1 2026, $6000.0 in Q4 2025, and $239000.0 in Q3 2025.